4SC AG EBITDA
Was ist das EBITDA von 4SC AG?
EBITDA von 4SC AG ist -€19.42
Was ist die Definition von EBITDA?
Das EBITDA ist das Ergebnis eines Unternehmens vor Zinsen, Steuern, Abschreibungen und Amortisationen und ist eine Buchhaltungsgröße, die anhand des Nettoergebnisses eines Unternehmens berechnet wird, bevor Zinsaufwendungen, Steuern, Abschreibungen und Amortisationen abgezogen werden, um die derzeitige operative Ertragskraft eines Unternehmens zu ermitteln.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA von Unternehmen in Health Care Sektor auf XETRA im Vergleich zu 4SC AG
Was macht 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Unternehmen mit ebitda ähnlich 4SC AG
- BrainChip Ltd hat EBITDA von -$19.48
- Seabridge Gold hat EBITDA von -CAD$19.45
- The Flowr hat EBITDA von -CAD$19.45
- Century Legend () hat EBITDA von -HKD$19.44
- Rubicon Minerals hat EBITDA von -CAD$19.43
- Rubicon Minerals hat EBITDA von -CAD$19.43
- 4SC AG hat EBITDA von -€19.42
- Venus Concept hat EBITDA von -$19.40
- Navios Maritime hat EBITDA von -$19.40
- Aqua Bio Technology ASA hat EBITDA von -kr19.39
- Northfield Capital hat EBITDA von -CAD$19.36
- Dore Copper Mining hat EBITDA von -CAD$19.36
- Dore Copper Mining hat EBITDA von -CAD$19.36